Sugi Predict

Sugi Predict / Compounds / SCHEMBL1016996

SCHEMBL1016996

SCHEMBL1016996

C#CCCCCCOS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.39
▸ CA1 P00915 2/20 0.39
▸ CA9 Q16790 2/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ PSMD10 O75832 1/20 0.38
▸ CYP24A1 Q07973 2/20 0.38
▸ STAT3 P40763 1/20 0.37
▸ GAA P10253 1/20 0.36
▸ G6PD P11413 1/20 0.36
▸ ESR1 P03372 1/20 0.35
▸ ESR2 Q92731 1/20 0.35
▸ MAOA P21397 1/20 0.35
▸ MAOB P27338 1/20 0.35
▸ CASP3 P42574 1/20 0.35
▸ CASP7 P55210 1/20 0.35
▸ VDR P11473 1/20 0.35
▸ CA2 P00918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21149355 1.00 CA12 (0.39) CA12CA1CA9ALDH1A1CYP3A4
SCHEMBL23832592 1.00 CA12 (0.39) CA12CA1CA9ALDH1A1CYP3A4
SCHEMBL1016953 1.00 CA12 (0.39) CA12CA1CA9ALDH1A1CYP3A4
SCHEMBL25362116 1.00 CA12 (0.39) CA12CA1CA9ALDH1A1CYP3A4
SCHEMBL8926866 1.00 CA12 (0.39) CA12CA1CA9ALDH1A1CYP3A4
SCHEMBL23015111 1.00 CA12 (0.39) CA12CA1CA9ALDH1A1CYP3A4
SCHEMBL25371249 1.00 CA12 (0.39) CA12CA1CA9ALDH1A1CYP3A4
SCHEMBL2845979 0.98 CA12 (0.40) CA12CA1CA9ALDH1A1CYP3A4
SCHEMBL278880 0.94 ALDH1A1 (0.41) CA12CA1CA9ALDH1A1CYP3A4
SCHEMBL31173815 0.90 ALDH1A1 (0.40) CA12CA1CA9ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624044-B2 SMARCA degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-05-12 — — US disclosed
EP-4731309-A1 KRAS PROTEOLYSIS TARGETING CHIMERAS Paq Therapeutics Inc. (US) 2026-04-29 — — EP disclosed
US-12404285-B2 KRAS G12D proteolysis targeting chimeras PAQ Therapeutics Inc. (US) 2025-09-02 — — US disclosed
US-20250114461-A1 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-04-10 — — US disclosed
EP-4519273-A1 KRAS G12D PROTEOLYSIS TARGETING CHIMERAS Paq Therapeutics Inc. (US) 2025-03-12 — — EP disclosed
US-20250051364-A1 KRAS G12D Proteolysis Targeting Chimeras PAQ Therapeutics Inc. (US) 2025-02-13 — — US disclosed
WO-2024263586-A1 KRAS PROTEOLYSIS TARGETING CHIMERAS PAQ Therapeutics Inc. (US) 2024-12-26 — — WO disclosed
US-12097261-B2 CDK2 degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-09-24 — — US disclosed
US-20240247000-A1 KRAS G12D Proteolysis Targeting Chimeras PAQ Therapeutics Inc. (US) 2024-07-25 — — US disclosed
CN-117715904-A CDK2 degrading agents and uses thereof 凯麦拉医疗公司 2024-03-15 — — CN disclosed
WO-2023215906-A1 KRAS G12D PROTEOLYSIS TARGETING CHIMERAS HANGZHOU JIJING PHARMACEUTICALTECHNOLOGY LIMITED (CN) 2023-11-09 — — WO disclosed
WO-2023156791-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-08-24 — — WO disclosed
US-20230110180-A1 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-13 — — US disclosed
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-09 — — US disclosed
WO-2022236058-A1 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-11-10 — — WO disclosed
CN-115197046-A Halogenation method of unsaturated hydrocarbon 华南理工大学 2022-10-18 — — CN disclosed
WO-2020251971-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-17 — — WO disclosed
US-8247595-B2 Organic sulfur compound and its use for controlling harmful arthropod SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-08-21 — — US disclosed
EP-2152668-B1 ORGANIC SULFUR COMPOUND AND ITS USE FOR CONTROLLING HARMFUL ARTHROPODS SUMITOMO CHEMICAL CO (JP) 2011-01-12 — — EP disclosed
US-20100160434-A1 ORGANIC SULFUR COMPOUND AND ITS USE FOR CONTROLLING HARMFUL ARTHROPOD SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-06-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051364-A1 KRAS G12D Proteolysis Targeting Chimeras KRAS, NRAS, HRAS CA12 1664/4885CA1 1263/4885CA9 735/4885
US-12404285-B2 KRAS G12D proteolysis targeting chimeras KRAS, NRAS, HRAS CA12 1664/4885CA1 1263/4885CA9 735/4885
US-12097261-B2 CDK2 degraders and uses thereof CDK2, CDK20, CDK1 CA12 2760/4885CA1 2858/4885CA9 2364/4885
US-20100160434-A1 ORGANIC SULFUR COMPOUND AND ITS USE FOR CONTROLLING HARMFUL ARTHROPOD C5, L3MBTL3, C1S CA12 1342/4885CA1 2754/4885CA9 1372/4885
US-20250114461-A1 CDK2 DEGRADERS AND USES THEREOF CDK2, CDK20, CDK1 CA12 2760/4885CA1 2858/4885CA9 2364/4885
US-12624044-B2 SMARCA degraders and uses thereof SMARCA1, SMARCC1, SMARCA2 CA12 3603/4885CA1 2045/4885CA9 3592/4885
US-20230110180-A1 CDK2 DEGRADERS AND USES THEREOF CDK2, CDK20, CDK1 CA12 2760/4885CA1 2858/4885CA9 2364/4885
US-20240247000-A1 KRAS G12D Proteolysis Targeting Chimeras KRAS, NRAS, HRAS CA12 1664/4885CA1 1263/4885CA9 735/4885
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCB1, SMARCE1 CA12 4324/4885CA1 2909/4885CA9 4211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.